VK2735 dosage

What VK2735 is

VK2735 is an investigational peptide that activates both the GLP-1 and GIP receptors and is being studied as a once-weekly injection and as an oral formulation. One 13-week phase 2 randomized trial has been published, and phase 3 trials are under way. It is not an approved medicine, and this entry is for research information only.

VK2735 is described as a GLP-1 receptor and GIP receptor dual agonist that incorporates the activities of both incretin hormones ^1. Receptor binding The VENTURE report states that VK2735 binds with high affinity to the GLP-1 receptor (IC50 188 nM) and the GIP receptor (IC50 325 nM), citing unpublished data from the sponsor ^1. No independent peer-reviewed pharmacology paper was located for this entry ^1.… How it works →

Schedules by time period

study arms from registered trials, laid out week by week. Each bar is what the label states or what investigators gave participants; none is a recommendation.

Doses given in human trials

• In VENTURE (NCT06068946), participants were randomized 1:1:1:1:1 to weekly subcutaneous VK2735 at 2.5, 5.0, 10 or 15 mg or matched placebo for 13 weeks, with titration to the final dose; the 15 mg group started at 5.0 mg and the others at 2.5 mg ^1,2.
• VANQUISH 1 (NCT07104500) is registered as a 78-week trial of once-weekly VK2735 7.5 mg, 12.5 mg or 17.5 mg versus placebo in an estimated 4,500 adults without type 2 diabetes ^5.
• VANQUISH 2 (NCT07104383) is registered with the same three dose arms and placebo in an estimated 1,100 adults with type 2 diabetes ^6.
• The oral phase 2 trial (NCT06828055) is registered with six daily oral dose arms and placebo over 13 weeks in 280 participants ^4.
• SUNRISE 1 (NCT07868835) is registered as a 68-week trial of three oral once-daily dose levels versus placebo in an estimated 560 adults without type 2 diabetes, and SUNRISE 2 (NCT07868939) as a trial in adults with type 2 diabetes ^7,8.
• VENTURE randomized 176 participants (about 35 per group); the total study lasted 23 weeks, comprising 4 weeks of screening, 13 weeks of treatment and about 6 weeks of safety follow-up ^1.
• The phase 1 registry record (NCT05203237; 92 enrolled) lists Part A (single escalating subcutaneous doses in healthy participants), Part B (escalating once-weekly subcutaneous doses for four weeks) and Part C (escalating once-daily oral doses for 28 days), each with placebo; dose amounts are not stated in the registry fields ^3.
• SUNRISE 2 (NCT07868939) is registered as a 68-week trial of three oral once-daily VK2735 dose levels versus placebo in an estimated 560 adults with type 2 diabetes ^8.

How long did human studies run?

• VENTURE: 13 weeks of treatment ^1. VANQUISH 1 and 2: primary endpoint at week 78 ^5,6. Oral phase 2: 13 weeks ^4. SUNRISE 1 and 2: 68 weeks ^7,8.

Who was excluded from the studies

• VENTURE excluded participants with diabetes or BMI above 50 ^1.
• VANQUISH 1 registry exclusion criteria include a self-reported body-weight change of 5% or more within 3 months, prior or planned obesity surgery or device-based therapy, current or past diabetes, glucose-lowering agents within 90 days, a personal or family history of medullary thyroid carcinoma or MEN 2, and a history of acute or chronic pancreatitis ^5.

Side effects reported in studies

• Gastrointestinal disorders (any)
  51-83% across VK2735 groups versus 37% placebo · VENTURE, 13 weeks ¹
• Nausea
  26-63% across VK2735 groups versus 20% placebo · VENTURE ¹
• Vomiting
  9-29% across VK2735 groups versus 0% placebo · VENTURE ¹
• Constipation
  20-29% across VK2735 groups versus 11% placebo · VENTURE ¹
• Adverse event leading to treatment discontinuation
  3-20% across VK2735 groups (20% at 15 mg) versus 0% placebo · VENTURE ¹
• Treatment-emergent serious adverse events
  3-6% across VK2735 groups versus 3% placebo · VENTURE ¹
• Anti-drug antibodies
  9-23% across VK2735 groups · VENTURE ¹

VK2735 draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

2 mg5 mg10 mg

2 · Water added

1 mL2 mL3 mL5 mL

3 · Amount per draw

mcgmg

4 · Syringe

30u50u100u

Your mix

10 mg + 2 mL water = 5 mg/mL

10 units holds 0.5 mg (500 mcg)

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	20	—
1 mL	10	—
1.5 mL	6.667	—
2 mL	5	—
2.5 mL	4	—
3 mL	3.333	—
5 mL	2	—

Supplies and handling

• Lyophilized vial
  Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
• Sterile diluent
  The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
• Graduated syringes
  Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
• Alcohol prep pads
  For wiping vial stoppers before each puncture.
• Nitrile gloves
  Clean gloves for aseptic handling.
• Sharps container
  Puncture-resistant container for used needles.

Storage

Storage conditions for research material are set by the supplier's documentation; lyophilized peptides are generally sensitive to heat, light and moisture.

• Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
• Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
• Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent

The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.

Shook the vial and it foamed

Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.

The solution is cloudy or has particles

Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.

The powder cake looks melted or shrunken before reconstitution

This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.

Liquid sprayed back when the needle was removed

Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status

Investigational as of 22 October 2026. An openFDA query of Drugs@FDA on that date returned no application record for VK2735 ^9, and its phase 3 trials are registered as active or not yet recruiting ^5,6,7,8.

United States (FDA)

VK2735 is investigational; an openFDA query of Drugs@FDA application data on 22 October 2026 returned no application record for it ^9.

Sport (WADA)

VK2735 is not named in the 2026 Prohibited List text reviewed. Section S0 covers pharmacological substances not addressed elsewhere on the List that have no current approval by any governmental regulatory health authority for human therapeutic use, including drugs under clinical development; athletes should consult WADA directly ^10.

Status varies by country and changes over time. How we describe regulatory status.

VK2735 compared with related compounds

Frequently asked questions

References

1. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study Obesity (Silver Spring). 2026
2. VK2735 for Weight Management Phase 2 (VENTURE, NCT06068946), registry record ClinicalTrials.gov. 2023
3. Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 (NCT05203237), registry record ClinicalTrials.gov. 2021
4. VK2735 for Weight Management Phase 2 (VENTURE Oral Dosing, NCT06828055), registry record ClinicalTrials.gov. 2024
5. VK2735 for Weight Management Phase 3 (VANQUISH 1, NCT07104500), registry record ClinicalTrials.gov. 2025
6. VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2, NCT07104383), registry record ClinicalTrials.gov. 2025
7. Oral VK2735 for Weight Management Phase 3 (SUNRISE 1, NCT07868835), registry record ClinicalTrials.gov. 2026
8. Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2, NCT07868939), registry record ClinicalTrials.gov. 2026
9. Drugs@FDA application data queried through openFDA for VK2735 (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
10. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
11. PubChem compound name search for VK2735 (no compound record returned on 22 October 2026) PubChem. 2026